With the growth and transformation of the mAb market, particularly with the recent rapid rise of biosimilars, a one-size-fits-all approach to protein purification is no longer viable. To address this, Cytiva developed two new protein A resins: the MabSelect SuRe 70 and the MabSelect PrismA X.

随着单克隆抗体市场的发展和转型，尤其是近年来生物类似物的迅速崛起，一种适用于所有情况的蛋白质纯化方法已不再可行。为此，Cytiva 开发了两种新的蛋白 A 填料：MabSelect SuRe 70 和 MabSelect PrismA X。

Sofie Stille, Vice President and General Manager, Resins and Technologies, Cytiva, says: “The different stages of drug development require different purification needs. As more molecules are being brought to clinic, we wanted to provide our customers with innovative and cost-effective options regardless of stage.

Cytiva树脂与技术部门副总裁兼总经理索菲·斯蒂尔表示：“药物开发的不同阶段对纯化的需求各不相同。随着越来越多的分子进入临床，我们希望为客户提供创新且经济高效的解决方案，无论处于哪个阶段。”

These new resins offer affordability without sacrificing quality.”.

这些新型树脂既经济实惠又不牺牲质量。

With these new resins, Cytiva has expanded its comprehensive protein A resin portfolio with additional options to further help customers reduce manufacturing expenses and increase flexibility, while maintaining the same high-quality customers expect.

通过这些新型树脂，Cytiva扩展了其全面的蛋白A树脂产品组合，增加了更多选择，进一步帮助客户降低生产成本、提高灵活性，同时保持客户期望的同样高质量。

Key features of the new products:

新产品的关键特性：

The need for affordability is especially relevant in the purification stage for preclinical or clinical production, where 20 batches are run at most. Whereas in commercial production, speed and performance becomes crucial.

在临床前或临床生产中的纯化阶段，经济实惠的需求尤其重要，因为最多运行20个批次。而在商业化生产中，速度和性能变得至关重要。

Sofie Stille adds: “At whatever stage or scale a customer is at, we can offer solutions that fit based on speed, performance, or affordability, each sustainably designed.”

索菲·斯蒂勒补充道：“无论客户处于哪个阶段或规模如何，我们都可以根据速度、性能或经济实惠提供合适的解决方案，每个方案都经过可持续设计。”

Committed to security of supply and sustainability

致力于供应安全与可持续性

MabSelect resins are based on agarose, a renewable raw material, aligning with Cytiva’s sustainability commitments. Since 2022, Cytiva owns its agarose manufacturing and processing plant in Denmark, geographically close to the Swedish resins manufacturing site. Cytiva has also taken steps to further boost its security of supply by adding a second manufacturing site located in North America.

MabSelect树脂基于可再生原料琼脂糖，符合Cytiva的可持续发展承诺。自2022年起，Cytiva在丹麦拥有了自己的琼脂糖生产和加工工厂，地理位置靠近瑞典的树脂生产厂。Cytiva还采取措施进一步增强其供应链的安全性，在北美增设了第二个生产基地。

The Muskegon, Michigan site has undergone complete renovations and is on track for tech transfer..

密歇根州穆斯克贡的工厂已经完成了全面翻新，并正在按计划进行技术转移。

By strengthening the offering of protein A resins in clinical production, Cytiva continues to build on global representation and support the mAb industry with innovative, reliable, and sustainable solutions.

通过加强在临床生产中蛋白质A树脂的产品供应，Cytiva继续扩大其全球影响力，并通过创新、可靠和可持续的解决方案支持单克隆抗体行业。

Learn more about the MabSelect SuRe 70 and MabSelect PrismA X resins.

了解有关 MabSelect SuRe 70 和 MabSelect PrismA X 树脂的更多信息。

Cytiva, the drop logo, MabSelect and MabSelect PrismA are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

Cytiva、水滴形标志、MabSelect 和 MabSelect PrismA 是 Global Life Sciences Solutions USA LLC 或其以 Cytiva 名义开展业务的附属公司的商标。

About Cytiva

关于Cytiva

At Cytiva, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers.

在Cytiva，我们的使命是推动和加速治疗药物的开发。我们在全球40多个国家拥有15,000名员工，致力于运用我们的专业知识和才能，为客户提供更高的灵活性、产能和效率。我们广泛而深入的工具与技术组合、全球规模以及业内领先的服务，为从发现到交付的各个环节提供了关键支持，客户涵盖科研人员、新兴生物技术公司、大规模生物制药企业以及合同制造商。

Learn more at cytiva.com..

请访问cytiva.com了解更多信息。

Media contact:

媒体联系人：

Tania Kimball

坦尼娅·金博尔

tania.kimball@cytiva.com

田妮娅·金博尔@思泰法.com

Media Contact APAC:

亚太地区媒体联系人：

Doug Kim

道格·金

Doug.kim@cytiva.com

道格.金@思拓凡.com

Source: cytivalifesciences.com

来源：cytivalifesciences.com